Last updated: September 24, 2026
Clomiphene citrate is an established, low-cost oral fertility drug with limited composition-of-matter protection and no biosimilar exposure. The commercial opportunity is therefore formulation-led rather than molecule-led. The strongest strategies involve robust immediate-release tablets, lower-cost manufacturing, patient-friendly packaging, differentiated dosage strengths, and carefully supported 505(b)(2) products for new delivery systems or patient populations.
What is the FDA status of clomiphene citrate?
Clomiphene citrate is an FDA-approved oral ovulatory stimulant indicated for the treatment of ovulatory failure in women seeking pregnancy. The reference product is Clomid, originally approved under NDA 016131. Generic clomiphene citrate tablets remain available in the United States through abbreviated new drug applications, or ANDAs.
| Attribute |
Status |
| Active ingredient |
Clomiphene citrate |
| Therapeutic class |
Selective estrogen receptor modulator and ovulation-induction agent |
| Common strength |
50 mg tablet |
| Administration |
Oral, usually once daily for a limited treatment cycle |
| Reference product |
Clomid |
| FDA pathway for generics |
ANDA |
| Current U.S. brand status |
Clomid is generally listed as discontinued from U.S. commercial marketing, while generic products remain available |
| Biosimilar relevance |
None; clomiphene citrate is a small molecule |
| Primary commercial form |
Immediate-release tablet |
The FDA label limits treatment duration because of ovarian enlargement, ovarian hyperstimulation, multiple pregnancy risk, visual symptoms, and other safety concerns. Product development must preserve dose accuracy and avoid excipients that create avoidable tolerability, stability, or dissolution problems. [1]
What patents protect clomiphene citrate?
The principal patent opportunity for clomiphene citrate has expired. The drug was discovered and commercialized decades ago, and generic entry has been established for many years. Current commercial value does not depend on blocking generic entry through the original active-ingredient patent.
What is the Orange Book status of clomiphene citrate?
The relevant Orange Book issues are regulatory rather than patent-driven:
- Generic clomiphene citrate products are approved through ANDAs.
- The reference product is associated with an old NDA rather than a newly protected chemical entity.
- No active, commercially significant composition-of-matter patent should be assumed to protect standard 50 mg immediate-release clomiphene citrate tablets.
- Orange Book patent listings must be checked against the current FDA publication because listings, delistings, and product marketing status can change. [2]
A company entering with a conventional immediate-release tablet would normally compete on manufacturing cost, supply reliability, distribution, packaging, and customer service rather than on patent exclusivity.
When does clomiphene citrate lose exclusivity?
Clomiphene citrate lost practical market exclusivity long ago. The original patent estate and regulatory exclusivity periods do not provide a current barrier to ordinary generic entry.
What generic entry risks exist?
Generic entry risk is already realized rather than prospective. A new sponsor faces:
- Price competition from existing ANDA holders.
- Pharmacy substitution pressure.
- Limited differentiation for a standard 50 mg tablet.
- Low switching costs for prescribers and pharmacies.
- Potential wholesaler concentration.
- Supply-chain competition for low-margin oral solid-dose manufacturing.
The commercial risk is not a sudden patent cliff. It is a mature-market erosion problem. A new product needs a lower cost base, a differentiated dosage form, a reliable shortage-management strategy, or a targeted channel such as specialty fertility clinics.
What excipients are used in clomiphene citrate tablets?
Clomiphene citrate tablets generally use conventional immediate-release oral excipients. Public labels for generic products identify combinations of common tablet ingredients, including lactose or another diluent, microcrystalline cellulose, starch or pregelatinized starch, povidone, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The exact composition differs by manufacturer and product. [3]
| Excipient function |
Typical options |
Strategic purpose |
| Diluent |
Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate |
Tablet mass, compressibility, cost control |
| Binder |
Povidone, pregelatinized starch, hydroxypropyl cellulose |
Granule strength and tablet integrity |
| Disintegrant |
Sodium starch glycolate, crospovidone, croscarmellose sodium |
Rapid tablet breakup |
| Glidant |
Colloidal silicon dioxide |
Powder flow and content uniformity |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Ejection and tooling protection |
| Film former |
Hypromellose, polyethylene glycol |
Identification, appearance, moisture protection |
| Colorant |
Approved iron oxides or other permitted colorants |
Product differentiation and identification |
The relevant development target is usually rapid and reproducible immediate release, not modified release. Any change that slows dissolution, increases variability, or affects dose uniformity can create regulatory risk without delivering a meaningful clinical benefit.
How should an excipient strategy be designed for clomiphene citrate?
A commercially sound excipient strategy should prioritize four objectives: manufacturability, dissolution, stability, and patient acceptability.
Which diluent is most commercially attractive?
Microcrystalline cellulose is a strong default where direct compression is feasible. It supports compact tablets and can reduce process complexity. Lactose remains commercially attractive because of cost and availability, but it requires attention to moisture, supplier qualification, and patient-specific intolerance concerns.
A lactose-free formulation can provide a modest marketing distinction for fertility clinics and direct-to-patient channels. It is not likely to support premium pricing by itself.
Which disintegrant best supports immediate release?
Crospovidone, croscarmellose sodium, and sodium starch glycolate can support rapid tablet breakup. Selection should be based on dissolution performance, tablet hardness, lubricant sensitivity, and stability rather than brand positioning.
For a low-dose active in a 50 mg tablet, blend uniformity is a central process issue. The sponsor should evaluate ordered mixing, geometric dilution, granulation endpoint, and segregation risk. The excipient choice cannot compensate for a weak content-uniformity process.
Is a film-coated clomiphene citrate tablet commercially useful?
Film coating can improve swallowability, reduce dusting, protect the tablet from handling damage, and support product identification. It can also enable a lactose-free, color-coded product family.
The coating should remain thin and rapidly dispersible. A heavy or poorly controlled coating may slow dissolution and increase process cost. Packaging with a high-barrier blister may provide more practical stability value than a complex coating system.
Are specialty excipients justified?
Specialty excipients are difficult to justify for a conventional 50 mg immediate-release tablet unless they solve a documented problem. Examples include:
- Co-processed excipients that support direct compression.
- Low-moisture excipients for improved stability.
- Taste-masking systems for orally disintegrating tablets.
- Solubilizers for liquid or semi-solid dosage forms.
- Natural-color systems for patient identification.
- Excipient systems designed for continuous manufacturing.
The economic threshold is high because conventional excipients are widely available and the active ingredient is inexpensive.
What formulations are protected or commercially differentiated?
Standard immediate-release tablets have little practical formulation exclusivity. Commercial differentiation is more plausible in dosage forms that require new pharmaceutical development and may support a 505(b)(2) application.
Potential formulation opportunities
| Formulation concept |
Commercial rationale |
Regulatory and technical burden |
| Lactose-free immediate-release tablet |
Patient positioning and broader excipient acceptability |
Low |
| Orally disintegrating tablet |
Convenience and swallowing support |
Moderate |
| Oral solution or suspension |
Flexible dosing and administration |
Moderate to high |
| Unit-dose blister packaging |
Cycle-based adherence and clinic dispensing |
Low |
| Combination fertility pack |
Coordinated treatment-cycle packaging |
Moderate |
| Enclomiphene-enriched product |
Isomer-specific positioning |
High; may raise new active-ingredient issues |
| Modified-release product |
Reduced dosing frequency |
High; limited clinical justification |
| Compounded liquid formulation |
Pediatric or special-use access |
Product-specific and channel-limited |
The strongest near-term opportunity is likely a well-controlled immediate-release tablet with cycle-specific packaging, dependable supply, and a lower-risk excipient profile. Modified-release and isomer-specific products require substantially greater clinical and regulatory investment.
Can excipients support a 505(b)(2) clomiphene product?
A 505(b)(2) strategy could be relevant where the product differs materially from the approved tablet in dosage form, route, dosing schedule, or patient-use profile. Excipients alone do not create a 505(b)(2) opportunity if the product is therapeutically equivalent to an existing tablet.
Potential 505(b)(2) concepts include:
- Orally disintegrating tablets for patients with swallowing difficulty.
- Liquid formulations for controlled administration.
- New packaging linked to a defined treatment regimen.
- A dosage form designed to improve adherence or reduce dosing errors.
- A new route of administration supported by clinical evidence.
The sponsor would need to establish that the new formulation has a credible clinical or pharmaceutical rationale. A simple excipient substitution normally fits more naturally within an ANDA or a conventional new drug development program, depending on the product’s equivalence and regulatory design.
What method-of-use patents and licensing opportunities exist?
Method-of-use patent opportunities are more plausible than new composition-of-matter claims, but broad claims covering ovulation induction with clomiphene citrate face substantial prior-art and obviousness pressure.
Potentially protectable areas may include:
- Patient-selection criteria.
- Defined dosing algorithms.
- Combination treatment with another fertility therapy.
- Treatment sequencing.
- Biomarker-guided use.
- Specific male infertility protocols.
- Adherence or monitoring systems tied to a drug product.
These opportunities require clinical evidence and precise claim drafting. The standard use of clomiphene citrate for ovulatory failure is mature and should not be treated as an open field for broad exclusivity.
There is no major licensing requirement for a company developing a conventional generic tablet because the active ingredient and routine excipients are broadly available. Licensing may become relevant for:
- Proprietary delivery technology.
- Isomer separation or enrichment technology.
- Specialty packaging platforms.
- Digital adherence systems.
- Fertility-clinic distribution networks.
- Combination products involving separately controlled intellectual property.
Which companies are challenging clomiphene citrate exclusivity?
Generic competition is established. The principal competitive group consists of generic manufacturers and contract manufacturers supplying clomiphene citrate tablets rather than companies pursuing active Paragraph IV litigation against a currently protected brand.
What is the Paragraph IV risk?
For a standard clomiphene citrate tablet, Paragraph IV risk is limited because the principal exclusivity period has expired. A new ANDA sponsor may still face:
- Product-specific patent listings, if any remain relevant.
- Labeling disputes.
- Pharmaceutical-equivalence or bioequivalence questions.
- Manufacturing-site and supply-chain issues.
- Commercial litigation unrelated to core molecule protection.
The absence of a strong current patent barrier does not eliminate regulatory or commercial risk. It changes the nature of that risk from patent launch timing to approval timing, price competition, and channel access.
What patent litigation affects clomiphene citrate?
Clomiphene citrate does not have the litigation profile of a recently approved specialty drug. The commercially relevant disputes are more likely to involve generic approval, supply contracts, trademarks, manufacturing quality, or later-developed formulations than infringement of an active basic patent.
A sponsor should review current court dockets, FDA Orange Book listings, ANDA certifications, and product-label databases before launch. No broad assumption of litigation-free entry should replace a product-specific freedom-to-operate review.
How does clomiphene citrate compare with enclomiphene?
| Factor |
Clomiphene citrate |
Enclomiphene |
| Product status |
Established FDA-approved drug |
Development and regulatory-status questions depend on the specific product |
| Composition |
Mixture of stereoisomers |
One stereoisomer |
| Main established use |
Female ovulation induction |
Investigational or nonstandard uses have included male hypogonadism and fertility |
| Generic competition |
Established |
Less mature |
| Excipient opportunity |
Low-to-moderate |
Potentially higher if a differentiated approved product exists |
| Patent opportunity |
Limited for legacy tablet |
Potentially stronger for formulation, purification, or method claims |
| Regulatory risk |
Lower for standard tablet |
Higher |
Enclomiphene may offer a more substantial lifecycle and intellectual-property strategy, but it cannot be treated as a routine excipient reformulation of clomiphene citrate. The active-ingredient identity, clinical evidence, regulatory pathway, and patent position require separate analysis.
What commercial opportunities exist for excipient suppliers and manufacturers?
The most realistic opportunities are operational and formulation-based.
Excipient suppliers
Suppliers can compete through:
- Consistent low-moisture grades.
- Direct-compression platforms.
- Co-processed diluent-disintegrant systems.
- Global regulatory documentation.
- Small-volume supply for fertility-focused manufacturers.
- Technical support for continuous manufacturing and process validation.
Premium pricing will be difficult unless the excipient reduces manufacturing steps, improves content uniformity, or solves a documented stability problem.
Drug manufacturers
Manufacturers can pursue:
- Low-cost ANDA tablets.
- Lactose-free products.
- Blister packs containing a complete treatment cycle.
- Clinic-focused packaging.
- Dual-source supply arrangements.
- Regional registration in markets with limited reliable supply.
- Contract manufacturing for fertility brands.
- Combination products that remain within applicable regulatory boundaries.
Geographic expansion may be more attractive in markets where infertility treatment is growing and generic supply is fragmented. The principal barriers are local registration, pharmacovigilance, distribution, pricing controls, and quality-system requirements rather than patent rights.
What revenue exposure and launch scenarios should investors consider?
A conventional clomiphene citrate launch is unlikely to support a high-margin specialty-drug valuation. The product has low active-ingredient cost, mature generic competition, and limited exclusivity.
| Launch scenario |
Expected commercial profile |
| Commodity 50 mg tablet |
Low margin, volume-dependent |
| Lower-cost private-label product |
Moderate volume potential, high price pressure |
| Fertility-clinic branded generic |
Better channel control, limited pricing premium |
| Cycle-specific blister pack |
Moderate differentiation and adherence value |
| Orally disintegrating tablet |
Potential premium, higher development burden |
| 505(b)(2) differentiated product |
Higher upside, materially higher clinical and regulatory risk |
| Enclomiphene product |
Greater IP potential, highest regulatory uncertainty |
Revenue exposure should be modeled against net price, pharmacy substitution, wholesaler discounts, manufacturing yield, and supply continuity. Public filings generally do not isolate clomiphene revenue with enough granularity to support a reliable product-level forecast.
Key Takeaways
- Clomiphene citrate is a mature generic small molecule with no biosimilar risk.
- Standard immediate-release tablets have limited patent and formulation exclusivity.
- The best excipient strategy emphasizes blend uniformity, rapid disintegration, stability, low cost, and reliable supply.
- Microcrystalline cellulose, lactose, starch-based binders, crospovidone, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate are commercially relevant conventional choices.
- Lactose-free tablets, orally disintegrating tablets, cycle-specific blister packaging, and clinic-focused distribution offer the most credible differentiation.
- A 505(b)(2) strategy requires a meaningful dosage-form, route, dosing, or clinical-use distinction; excipient substitution alone is usually insufficient.
- Enclomiphene is a separate development and patent opportunity, not a routine reformulation of clomiphene citrate.
- Generic launch economics depend more on cost, supply reliability, channel access, and geographic registration than on legacy patent rights.
FAQs About Clomiphene Citrate Excipients and Market Entry
Is clomiphene citrate a high-value target for novel excipient technology?
Usually not for a conventional tablet. Novel excipients become more defensible when they improve dissolution, continuous manufacturing, dose uniformity, stability, or a differentiated dosage form.
Can a lactose-free clomiphene tablet obtain market exclusivity?
A lactose-free composition may support a product distinction but normally does not create meaningful exclusivity by itself. Patentability would depend on an inventive formulation and defensible claims.
Does clomiphene citrate require a biosimilar development program?
No. Clomiphene citrate is a chemically synthesized small molecule. Generic approval generally proceeds through an ANDA rather than a biologics license application or biosimilar pathway.
Is an orally disintegrating clomiphene tablet commercially attractive?
It may support differentiation for patients with swallowing difficulties and improve product branding. The opportunity is constrained by limited treatment duration, low active-ingredient cost, and the need to demonstrate acceptable dissolution, stability, packaging, and bioequivalence.
Can a company patent the use of clomiphene citrate in male infertility?
A broad claim covering male infertility is vulnerable to prior art and obviousness challenges. Narrow claims based on patient selection, dosing, sequencing, biomarkers, or combination treatment may have stronger prospects if supported by clinical data.
References
- U.S. Food and Drug Administration. (n.d.). Clomid (clomiphene citrate) prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
- National Library of Medicine. (n.d.). DailyMed: Clomiphene citrate tablet labeling.
- U.S. Food and Drug Administration. (2019). Applications covered by Section 505(b)(2).
- U.S. Food and Drug Administration. (2022). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin.
